Big Pharma outfits join forces on comparator network

TransCelerate BioPharma has notched another pre-competitive victory for its Big Pharma and biotech members. The Philadelphia nonprofit has set up a network for companies to score comparator drugs for clinical trials, seeking to overcome bottlenecks in clinical development from uncertain supplies of such medicines. (Sometimes companies resort to buying comparator drugs on the open market, an inefficient and costly way to acquire the medicines.) "For the first time, this TransCelerate initiative will allow industry-wide alignment and improved supply chain around comparator drugs for clinical trials that is so critical to enhancing patient safety and improving the efficiency of clinical trials," said Dr. Paul Stoffels, chief scientific officer and worldwide chairman, pharmaceuticals at Johnson & Johnson ($JNJ), which spearheaded the nonprofit. More

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.